News

Based on the Phase 2 safety and efficacy results, along with guidance from the FDA and EMA, Revance plans to proceed to a Phase 3 program in cervical

This includes three marketed products: recently approved and launched Vabomere (vaborbactam/meropenem), and established commercial products Orbactiv (oritavancin) and Minocin IV (minocycline).  The acquisition was unanimously approved by Melinta’s

Erenumab delivered clinically meaningful and statistically significant differences from placebo for all primary and secondary endpoints in the study, dubbed Strive.  Erenumab functions by targeting and inhibiting the Calcitonin Gene-Related Peptide

The trial showed statistically significant and dose dependent increases in lean body mass and less head following treatment with VK5211 compared against placebo. In addition, the study also reached secondary endpoints,

Titan and Molteni, a European-based pharmaceutical company focused on treatments for pain and drug addiction, expect to enter into the definitive license and distribution agreement during the first

The randomized, placebo-controlled, double-blind phase 1 trial will feature 240 male and female subjects aged between 18 and 49. It will assess the safety and immunogenicity of the investigational

Genentech will conduct the multicenter trial, which will enroll approximately 40 patients in the initial phase of the study. “We are pleased to be working with one of

Eylea injection is a vascular endothelial growth factor (VEGF) inhibitor formulated as an injection for the eye. It is designed to inhibit the growth of new blood vessels

The ATLAS-2M study is designed to demonstrate the non-inferior antiviral activity, at 48 weeks of treatment, of long-acting cabotegravir and long-acting rilpivirine administered every eight weeks compared with